Printer Friendly

United States : USFDA approves Dr. REDDYS's Duloxetine equivalent generic version of Eli Lillys Cymbalta.

Dr. Reddy's Laboratories ( RDY) announced that it has brought in Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg, a therapeutic equivalent generic version of CYMBALTAA (Duloxetineu Delayed-Release Capsules) in the US market.

United States Food & Drug Administration (USFDA) ratified Dr. Reddy's ANDA.

As per the IMS Health, CYMBALTAA brand and generic had U.S. sales of nearly $5.04 Billion MAT for the most recent twelve months ending in April 2014.

In various bottle counts, Dr. Reddy's Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg are acquirable.

CYMBALTAA is a registered trademark of Eli Lilly and firm.

2014 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).
COPYRIGHT 2014 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Jul 1, 2014
Previous Article:United States : VESTAS secures two contracts totaling 450MW.
Next Article:United States : Simpson Thacher Represents Adeptus Health Inc. in Initial Public Offering.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters